Welcome to the Reuters.com BETA. Read our Editor's note on how we're helping professionals make smart decisions.
Read more
Sign In
April 15, 20214:40 AM PDTLast Updated 3 months ago
Healthcare & Pharmaceuticals
WHO expects decision on emergency listing for Chinese vaccines soon

3 minute read
A nurse holds a syringe containing a coronavirus disease (COVID-19) vaccine made by the Beijing Institute of Biological Products, a unit of Sinopharm subsidiary China National Biotec Group (CNBG), at a vaccination center during a government-organized visit, in Beijing, China, April 15, 2021. REUTERS/Thomas Peter
ZURICH, April 15 (Reuters) - The World Health Organization will decide late this month or in May on emergency use listings for COVID-19 vaccines from Sinopharm (1099.HK) and Sinovac (SVA.O) following an extended review, a WHO European region official said on Thursday.
"We are in touch with them to review the dossiers that have been submitted by both vaccine manufacturers," WHO-Europe vaccination expert Siddhartha Datta told a virtual press conference. "We will be hearing about a decision on the emergency use listing in April or early May, so please keep an eye on that."
A WHO panel in final stages of review of the Chinese vaccines has said that a decision for at least one could come on April 26, while a second meeting has been planned for May 3, should more time be needed to make a decision on both shots.
Such an emergency WHO listing is a prerequisite for purchase by the COVAX vaccine-sharing facility designed to get shots to poorer countries. It also helps guide countries with less developed regulatory systems about a vaccine's safety and efficacy.
So far, the WHO has issued emergency listings for Pfizer and BioNTech's (22UAy.DE) COVID-19 vaccine, as well as versions of AstraZeneca's (AZN.L) vaccine made by the Serum Institute of India and South Korea's AstraZeneca-SKBio.
CanSino's vaccine relies on a viral vector to deliver DNA to prompt an immune response, a technique similar to that used in both AstraZeneca's and Johnson & Johnson's (JNJ.N) vaccines now being investigated for their association with very rare blood clots combined with low platelet counts.
CanSino has said there have been no reports of blood clots. read more
Sinovac's vaccine, being used in places including Hong Kong and Brazil, relies on inactivated coronaviruses to generate an immune response, a technique used for decades including against polio. read more
Reporting by John Miller; Editing by Hugh Lawson
Our Standards: The Thomson Reuters Trust Principles.
More from Reuters
Play video on original page

Read Next
Healthcare & Pharmaceuticals
CureVac's COVID-19 vaccine misses efficacy goal in mass trial
1:51 PM PDT
Middle East
Abu Dhabi receives first shipment of coronavirus medication Sotrovimab - tweet
1:11 PM PDT
Healthcare & Pharmaceuticals
Factbox: Latest on the worldwide spread of the coronavirus
12:59 PM PDT
Healthcare & Pharmaceuticals
Regeneron antibodies help asymptomatic and hospitalized patients; some lymph node cancers limit vaccine response
12:43 PM PDT

Sign up for our newsletter
Subscribe for our daily curated newsletter to receive the latest exclusive Reuters coverage delivered to your inbox.
Healthcare & Pharmaceuticals
Healthcare & Pharmaceuticals · 9:58 AM PDT
Regeneron’s antibody therapy cuts deaths among some hospitalised COVID-19 patients -study
A COVID-19 antibody cocktail developed by Regeneron Pharmaceuticals Inc (REGN.O) and Roche (ROG.S) reduced deaths in hospitalised patients whose own immune systems had failed to produce a response, a large British study found on Wednesday.
Healthcare & Pharmaceuticals
EU says J&J to miss vaccine supply target in second quarter
8:57 AM PDT
Healthcare & Pharmaceuticals
Novartis prostate cancer drug receives U.S. FDA breakthrough designation
10:42 AM PDT
Healthcare & Pharmaceuticals
COVID-19 vaccine access, not acceptance, key issue in Americas -PAHO
10:46 AM PDT
Healthcare & Pharmaceuticals
U.S. administers 312.9 mln doses of COVID-19 vaccines - CDC
11:27 AM PDT
About Reuters
About Reuters
Reuters News Agency
Brand Attribution Guidelines
Reuters Leadership
Reuters Fact Check
Reuters Diversity Report
Stay Informed
Download the App
Information you can trust
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world's media organizations, industry events and directly to consumers.
Follow Us
Thomson Reuters Products
Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology.
The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs.
The industry leader for online information for tax, accounting and finance professionals.
Refinitiv Products
Information, analytics and exclusive news on financial markets - delivered in an intuitive desktop and mobile interface.
Refinitiv Data Platform
Access to real-time, reference, and non-real time data in the cloud to power your enterprise.
Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks.
Advertise With Us
Advertising Guidelines
Terms of Use
Site Feedback

All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2021 Reuters. All rights reserved